INOVIO Advances COVID-19 DNA Vaccine Study in China

INOVIO and Advaccine Biopharmaceuticals Suzhou Co., Ltd. announced the successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. The dosing regimen involves two vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg dosing levels and is similar to the Phase 2 segment of Phase 2/3 clinical trial in the USA.

Dr. Bin Wang, Founder of Advaccine, said in a press statement: "After the completion of dosing for Phase 1 trial subjects at Huashan Hospital in Shanghai, China, with regulatory approval, Advaccine quickly launched the Phase 2 clinical trial with Jiangsu Provincial CDC team."